Amylyx prices public offering of 14.09 million shares at $35.50

Amylyx Pharmaceuticals entered into an underwriting agreement on August 19, 2026 with Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital as representatives of the underwriters. The agreement covers the issuance and sale of an aggregate of 14,090,000 shares of common stock at a price to the public of $35.50 per share.¹

The underwriters were also granted a 30-day option to purchase up to 2,113,500 additional shares at the public offering price less discounts and commissions.¹

Amylyx expects aggregate net proceeds of approximately $471.7 million after deducting underwriting discounts, commissions, and other estimated offering expenses, or approximately $542.5 million if the underwriters exercise their option in full.¹

The company said it intends to use the net proceeds, together with existing cash, cash equivalents, and marketable securities, to fund the potential commercial launch of avexitide in the United States if approved, including securing additional manufacturing capacity, as well as for research and development, working capital, and other general corporate purposes.¹

The offering is expected to close on August 21, 2026, subject to customary closing conditions.¹ All shares in the offering are being sold by the company.¹

The offering is being made under a prospectus supplement dated August 19, 2026, filed with the SEC on August 20, 2026, along with a base prospectus under a Form S-3ASR registration statement that became automatically effective on March 3, 2026.¹